MACROGENICS, INC. Contract Liability (Deferred Revenue)
MACROGENICS, INC. (MGNX) had Contract Liability (Deferred Revenue) of $55.50 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Deferred Revenue, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2026-08-14
- 2026-06-30: Contract with Customer, Liability, Current $55.50M.
- 2026-03-31: Contract with Customer, Liability, Current $67.99M.
- 2025-12-31: Contract with Customer, Liability, Current $1.28M; Contract with Customer, Liability, Current as first filed $10.92M.
- 2025-09-30: Contract with Customer, Liability, Current $10.30M.
| Period end | Contract with Customer, Liability, Current | Contract with Customer, Liability, Current as first filed |
|---|---|---|
| 2026-06-30 | $55.50M 10-Q · filed 2026-08-14 | |
| 2026-03-31 | $67.99M 10-Q · filed 2026-05-13 | |
| 2025-12-31 | $1.28M 10-Q · filed 2026-08-14 | $10.92M 10-Q · filed 2026-05-13 |
| 2025-09-30 | $10.30M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $7.87M 10-Q · filed 2025-08-14 | |
| 2025-03-31 | $15.62M 10-Q · filed 2025-05-13 | |
| 2024-12-31 | $16.32M 10-Q · filed 2025-11-12 | |
| 2024-09-30 | $23.31M 10-Q · filed 2024-11-05 | |
| 2024-06-30 | $23.82M 10-Q · filed 2024-08-06 | |
| 2024-03-31 | $22.84M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $21.65M 10-Q · filed 2024-11-05 | |
| 2023-09-30 | $18.58M 10-Q · filed 2023-11-06 | |
| 2023-06-30 | $9.67M 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $9.25M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $9.99M 10-Q · filed 2023-11-06 | |
| 2022-09-30 | $7.08M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $11.56M 10-Q · filed 2022-08-08 | |
| 2022-03-31 | $25.56M 10-Q · filed 2022-05-03 | |
| 2021-12-31 | $20.65M 10-Q · filed 2022-11-03 | |
| 2021-09-30 | $16.31M 10-Q · filed 2021-11-02 | |
| 2021-06-30 | $16.57M 10-Q · filed 2021-07-29 | |
| 2021-03-31 | $3.52M 10-Q · filed 2021-04-29 | |
| 2020-12-31 | $4.46M 10-Q · filed 2021-11-02 | |
| 2020-09-30 | $9.26M 10-Q · filed 2020-11-04 | |
| 2020-06-30 | $9.27M 10-Q · filed 2020-07-31 | |
| 2020-03-31 | $9.51M 10-Q · filed 2020-05-05 | |
| 2019-12-31 | $10.70M 10-Q · filed 2020-11-04 | |
| 2019-09-30 | $23.57M 10-Q · filed 2019-11-06 | |
| 2019-06-30 | $14.45M 10-Q · filed 2019-07-31 | |
| 2019-03-31 | $18.09M 10-Q · filed 2019-05-01 | |
| 2018-12-31 | $21.72M 10-Q · filed 2019-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |